Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04984382
Other study ID # 2021SDU-QILU-G004
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 26, 2021
Est. completion date September 2022

Study information

Verified date November 2021
Source Shandong University
Contact Xiuli Zuo, MD, PhD
Phone 86 15588818685
Email zuoxiuli@sdu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The researchers recruited gastroenterologists. Physician subjects recruited Helicobacter pylori-positive patients before and after receiving standardized training on Helicobacter pylori eradication. There are no restrictions on treatment options and drugs during the trial. Compare the eradication rate, adverse reaction rate, and patient compliance before and after physician training.


Description:

The researchers recruited gastroenterologists to participate in the study, and gastroenterologists recruited Helicobacter pylori-positive patients. In this process, the patient population is not limited, and the eradication program is not limited. Gastroenterologists can follow up or not follow up according to their original diagnosis and treatment. Researchers follow up and record the patient's medication status and adverse reactions in the medication process by phone or WeChat, and evaluate patient compliance. Record the eradication rate. After waiting for all patients admitted by gastroenterologists to be eradicated and re-examined, we will provide standardized Helicobacter pylori eradication training for gastroenterologist subjects. After the training, gastroenterologists recruit Helicobacter pylori-positive patients here. In this process, the patient population is not limited, and the eradication program is not limited. Gastroenterologists can follow up or not follow up according to their original diagnosis and treatment. Researchers follow up and record the patient's medication status and adverse reactions in the medication process by phone or WeChat, and evaluate patient compliance. Record the eradication rate. Compare the eradication rate, the incidence of adverse reactions, and the compliance of the patients before and after the training of the gastroenterologists.


Recruitment information / eligibility

Status Recruiting
Enrollment 2000
Est. completion date September 2022
Est. primary completion date September 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - 1.Physician specialized in gastroenterology. - 2.Diagnosis and treatment conditions for H. pylori exist in the hospital where the gastroenterology doctor is located. (C13 urea breath test, C14 urea breath test, rapid urease test, stool H. pylori antigen test, histopathological test, H. pylori culture, any of the above) Exclusion Criteria: - 1.Those who are unable or unwilling to provide informed consent. - 2.Patients with H. pylori have never been diagnosed and treated.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Standardized training on Helicobacter pylori eradication treatment
Standardized training on Helicobacter pylori eradication treatment

Locations

Country Name City State
China Xiuli Zuo Jinan Shandong

Sponsors (1)

Lead Sponsor Collaborator
Shandong University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Eradication rate The eradication rate of before and after the gastroenterologists receiving standardized Helicobacter pylori eradication training 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT05061732 - Helicobacter Pylori Eradication and Follow-up Phase 4
Completed NCT03779074 - Comparing the Efficacy of Hybrid, High-dose Dual and Bismuth Quadruple Therapies Phase 3
Completed NCT06076681 - A Study to Evaluate Preliminary Helicobacter Pylori Eradication After Multiple Doses of TNP-2198 Capsules Combined With Rabeprazole Sodium Enteric-coated Tablets, or Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules Phase 1/Phase 2
Recruiting NCT05329636 - Auto Fecal Microbial Transplant Post Helicobacter Pylori Antibiotic Therapy Phase 1/Phase 2
Recruiting NCT05065138 - Comparison of Helicobacter Pylori Eradication Effect Before and After Training of Gastroenterologists N/A
Completed NCT05049902 - Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication Phase 4
Not yet recruiting NCT06200779 - Tailored vs. Empirical Helicobacter Pylori Infection Treatment Phase 4
Not yet recruiting NCT06037122 - Efficacy of Low-dose Vonoprazan for Helicobacter Pylori Eradication
Completed NCT04617613 - Comparing Different Regimens for Eradication of Helicobacter Pylori in Kuwait Phase 4
Withdrawn NCT02552641 - Food Effect on the Eradication Rate of H. Pylori With Triple Therapy With Esomeprazole Phase 4
Completed NCT02873247 - Standardize Communication With General Practitioner & Patient for Improved Eradication of Helicobacter Pylori
Completed NCT02557932 - Comparison of 7-day PPI-based Standard Triple Therapy and 10-day Bismuth Quadruple Therapy for H. Pylori Eradication Phase 3
Recruiting NCT02249546 - Efficacy of Acetylcysteine-containing Triple Therapy in the First Line of Helicobacter Pylori Infection Phase 4
Completed NCT01933659 - Anti-H. Pylori Effect of Deep See Water Phase 3
Unknown status NCT01464060 - 14-day Quadruple Hybrid vs. Concomitant Therapies for Helicobacter Pylori Eradication Phase 4
Completed NCT00841490 - Oral H. Pylori Prevalence in Intellectually & Developmentally Disabled Adults N/A
Recruiting NCT05549115 - Susceptibility-Guided Sequential Therapy for Helicobacter Pylori Infection N/A
Recruiting NCT05728424 - One vs Two Weeks Treatment for H.Pylori Eradication A RANDOMIZED NON-INFERIORITY PLACEBO CONTROLLED TRIAL Phase 3
Recruiting NCT05997433 - Efficacy of 7-day Versus 14-day Bismuth Quadruple Therapy for the Eradication of Helicobacter Pylori(SHARE2302) N/A
Completed NCT04708405 - The Relationship Between Helicobacter Pylori Infection and Inflammatory Bowel Diseases: A Real-life Observation